Otsuka Holdings

Otsuka Holdings é uma das ...

• Forbes Global 2000 (#770);
• Nikkei 225;
• Topix.

Otsuka Holdings é uma empresa listada sob o símbolo 4578 (JP).

Otsuka Holdings tem presença direta em 10 países.

Otsuka Holdings possui 25 subsidiárias incluindo Astex, Astex Pharmaceuticals e Cambridge Isotope Laboratories.

Eles estão dentro:

• Farmacêutica54%
• Equipamentos Médicos27%
• Outro19%

Veja o organograma con seus 241 executivos principais

Biografias mais buscadas da Otsuka Holdings

• Tatsuo Higuchi, President, Chief Executive Officer, Chairman of Th...
• Yukio Matsutani, Independent Director
• Ko Sekiguchi, Independent Director

Criar um alerta
para seguir os movimentos de executivos da Otsuka Holdings.

Otsuka Holdings possui 1.833 concorrentes concorrentes IQVIA (Estados Unidos), Siemens Healthineers (Alemanha) e TimelyCare (Estados Unidos).

Popular M&A news in Saúde

• SmarterDx acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de maio de 2024).
• KKR has announced the acquisition of Healthium  (publicado em 9 de maio de 2024).
• Rad AI acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 7 de maio de 2024).

Outros contatos sugeridos na indústria do Saúde

• Ari Bousbib - Chairman and Chief Executive Officer da IQVIA
• Bryan Roberts - Director da Included Health
• Paulo Junqueira Moll - Chief Executive Officer da Rede D'Or Sao Luiz

Saiba mais sobre a indústria do Saúde >

Últimos comunicados de imprensa de Otsuka Holdings

• Carbonated Nutritional Drink "ORONAMIN C DRINK" Debuts in Egypt｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Carbonated Nutritional Drink "ORONAMIN C DRINK" Debuts in Egypt｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment of Hypercholesterolemia｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Novartis launches Entresto® Granular Tablets for Pediatric Use, a formulation dedicated for pediatric patients｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Submission of an Application for the First Hematological Malignancies Gene Panel Test in Japan｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• FACEDUO Emotion Recognition Training VR now available - Support for those with developmental conditions such as autism spectrum disorder (ASD), which makes it difficult to read emotions -｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry in the U.S.｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• U.S. Food and Drug Administration (FDA) Clearance of Rejoyn® First Prescription Digital Therapeutic Authorized in the U.S. for the Adjunctive Treatment of Major Depressive Disorder (MDD) symptoms｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka and Sumitomo Revise License Agreement - Otsuka holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide - ｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• View more press releases Close

Redes sociais sobre Otsuka Holdings

• Otsuka Holdings na Wikipedia, Google News e Yahoo Finance
• Otsuka Holdings na LinkedIn, Twitter e YouTube

Contate seus executivos por e-mail agora, incluindo Tatsuo Higuchi

Ligue para a Otsuka Holdings em +81 36...

Veja o organograma

Register to receive your alert

Relatório um erro